CommercialPrior AuthMedium impact
Promacta (eltrombopag)
Blue Cross & Blue Shield of Mississippi·MS · Hematology, Gastroenterology, Infectious Disease·Medical Policy
We identified it
Jun 20, 2026
Summary
Blue Cross Blue Shield of Mississippi updated their prior authorization policy for Promacta (eltrombopag), a medication used to treat low platelet counts in immune thrombocytopenia, hepatitis C-related thrombocytopenia, and severe aplastic anemia. The policy requires prior authorization with specific medical criteria including failed trials of other therapies and specialist consultation.
Action Required
Immediately: Billing team must ensure prior authorization is obtained for all Promacta (eltrombopag) prescriptions for BCBSMS patients. Providers must document specific medical criteria including diagnosis, platelet counts, failed trials of corticosteroids/IVIG/rituximab (for ITP), and specialist consultation. Update encounter forms to remind providers of PA requirement. Claims will be denied without proper authorization.